Glasdegib Maleate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Glasdegib Maleate |
| DrugBank ID | DB11978 |
| Brand Names (EU) | Daurismo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.10% |
Approved Indication (EMA)
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute myeloid leukemia with t(8;21)(q22;q22) translocation | 99.10% | DL |
| 2 | acute myeloid leukemia with CEBPA somatic mutations | 99.07% | DL |
| 3 | acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) | 99.05% | DL |
| 4 | bulbar polio | 98.79% | DL |
| 5 | acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor | 98.73% | DL |
| 6 | therapy related acute myeloid leukemia and myelodysplastic syndrome | 98.57% | DL |
| 7 | acute myeloid leukemia with t(8;16)(p11;p13) translocation | 98.46% | DL |
| 8 | acute myeloid leukemia with t(9;11)(p22;q23) | 98.28% | DL |
| 9 | 5q35 microduplication syndrome | 98.12% | DL |
| 10 | acute myeloid leukemia and myelodysplastic syndromes related to radiation | 98.07% | DL |
| 11 | acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent | 98.07% | DL |
| 12 | acute myeloid leukemia with t(6;9)(p23;q34) | 98.06% | DL |
| 13 | inherited acute myeloid leukemia | 97.93% | DL |
| 14 | unclassified acute myeloid leukemia | 97.85% | DL |
| 15 | neuralgic amyotrophy | 97.71% | DL |
| 16 | amyotrophic neuralgia | 97.57% | DL |
| 17 | acute myeloid leukemia with minimal differentiation | 97.52% | DL |
| 18 | myeloid leukemia | 97.48% | DL |
| 19 | acute myeloblastic leukemia with maturation | 97.42% | DL |
| 20 | acute myeloid leukemia with NPM1 somatic mutations | 97.28% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.